MARLBOROUGH, Mass.,
Nov. 10, 2016 /CNW/ -- Hologic, Inc.
(Nasdaq: HOLX) announced today that it has obtained approval from
Health Canada for the Company's hepatitis C and B assays. The
Aptima® HCV and HBV Quant assays are nucleic acid
amplification tests for the quantitative detection of RNA from
hepatitis C, and DNA from hepatitis B-infected patients.
These assays supplement the already available Aptima HIV-1 Quant
assay, rounding out the Company's virology portfolio on the
Panther® system in Canada.
The Aptima HCV and HBV Quant assays provide excellent
performance in sensitivity and precision parameters, along with
sample-to-result automation on the Panther system. Both assays
provide coverage across a wide linear range and employ multiple
layers of protection for viral detection and quantitation across
all major genotypes.
"The evolution of the hepatitis C treatment landscape has
enabled clinicians to better manage the disease, and the Aptima HCV
Quant Dx assay plays an essential role by aiding in the diagnosis
of infection and evaluating patients' response to antiviral
therapy," said Tom West,
president, Diagnostic Solutions Division at Hologic. "For HBV, our
test provides accurate, reliable monitoring that contributes to the
selection of effective treatment."
The Aptima HCV and HBV Quant assays run on Hologic's Panther
system, a market-leading, integrated platform that fully automates
all aspects of testing. The system substantially reduces hands-on
time for laboratories by providing random and continuous access
with rapid turnaround time. With the Panther system, laboratorians
can run viral load assays for HIV-1, HCV and HBV in parallel and
from a single patient sample.
"Laboratories are increasingly seeking to consolidate menu onto
a single platform," said West. "Increasing the range of assays that
can be run on the Panther system helps labs reach their efficiency
objectives."
The Aptima HCV and HBV Quant assays join a growing list of tests
available on the Panther system in the Canadian market, which
includes an HIV-1 viral load assay and a menu of tests for sexually
transmitted infections (chlamydia/gonorrhea, trichomonas and HPV
(human papillomavirus).
To learn more about the Aptima HIV, HCV and HBV Quant assays,
please visit
http://www.hologic.com/products/clinical-diagnostics-and-blood-screening/assays-and-tests.
The Aptima HIV-1, HCV, and HBV Quant assays are not currently
available for sale in the United
States.
About Hologic
Hologic, Inc. is a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products. The company's core business
units focus on diagnostics, breast health, GYN surgical, and
skeletal health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic Forward-Looking Statements
This press release
may contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic's
diagnostic products. There can be no assurance these products will
achieve the benefits described herein or that such benefits will be
replicated in any particular manner with respect to an individual
patient. The actual effect of the use of the products can only be
determined on a case-by-case basis depending on the particular
circumstances and patient in question. In addition, there can be no
assurance that these products will be commercially successful or
achieve any expected level of sales. Hologic expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any such statements presented herein to reflect any
change in expectations or any change in events, conditions or
circumstances on which any such statements are based.
Hologic, The Science of Sure, Aptima and Panther are registered
trademarks of Hologic, Inc. in the United
States and/or other countries.
Hologic Investor Contact
Michael Watts
Vice President, Investor Relations and Corporate Communications
+1 (858) 410-8588
michael.watts@hologic.com
Hologic Media Contact
Jane
Mazur
Senior Director, Divisional Communications
+1 (585) 355-5978
jane.mazur@hologic.com
SOURCE Hologic, Inc.